Lowering of very long chain fatty acids in patients with X-linked adrenoleukodystrophy (X-ALD): A biochemical study.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON22008

Enrollment

Registered

2006-04-06

Start date

2006-08-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

1. All patients participating in the trial will comply to a diet (American Heart Association level 1). 2. All patients will receive 6 months of placebo and 6 months of lovastatin 40 mg daily in ran

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male patients with X-ALD (confirmed by biochemical analysis or mutation analysis of the ABCD1 gene); 2. 18 years or older; 3. Able to give informed consent and visit the hospital; 4. No contraindications for use of trial medication.

Exclusion criteria

Exclusion criteria: 1. Use of another cholesterol lowering drug; 2. Liver disease or CK more than 3 times baseline level; 3. Use of very long chain fatty acid lowering therapy (e.g. Lorenzo's oil) in the 8 weeks preceding the study.

Design outcomes

Primary

Measure	Time frame
Very long chain fatty acid levels (in plasma and erythrocytes).	—

Contacts

Public ContactM. Engelen

Academic Medical Center (AMC), Department of Neurology, P.O. Box 22660.

M.Engelen@amc.uva.nl+31 (0)20 5662044

Outcome results